Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers | ANNALS OF ONCOLOGY |